Antonino Carbone is an expert in Hematology at Centro di Riferimento Oncologico (Italy). Antonino Carbone has authored 276 publications, the most recent in 2026, and is an investigator in 1 clinical trial. SLR score: 992 (community average: 125). How the SLR is computed.

LeadR Profile

Antonino Carbone Centro di Riferimento Oncologico Italy
992 ScienceLeadR Reputation 992
Network Map

Hematology

Subspecialties: Oncology - Immunology

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 1997 - 2026

Source: PubMed

Centro di Riferimento Oncologico

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 276

Citations

Citations: 11 877 1st author: 82 Last author: 51 Unique author: 12


Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Classic Hodgkin Lymphoma Beyond the Lymph Node: A Systemic Immunobiological Paradigm.
PMID 42279396 — chemokine ccl17, cells, chemokines, lymph nodes, hodgkin disease, lymphoma, neoplasms, lymph, therapeutics
Cancers (Basel)20260
Predictors of sensitivity to immune therapies in classic Hodgkin lymphoma.
PMID 42027746 — cells, major histocompatibility complex, hodgkin disease, lymphoma, biomarkers, therapeutics
Blood Neoplasia20260
Predictors of first line treatment failure in classic Hodgkin lymphoma: A comprehensive review.
PMID 40953759 — cells, hodgkin disease, lymphoma, macrophages, neoplasms, treatment failure, biomarkers, therapeutics, hematologic diseases
Crit Rev Oncol Hematol20250
Hodgkin Lymphoma Classification-From Historical Concepts to Current Refinements.
PMID 40941026 — cells, lymphocytes, hodgkin disease, lymphoma, classification, diagnosis, therapeutics, b-lymphocytes
Cancers (Basel)20250
Immune Checkpoint Molecules in Hodgkin Lymphoma and Other Hematological Malignancies.
PMID 40723175 — hodgkin disease, hematologic neoplasms, lymphoma, neoplasms, immune checkpoint inhibitors, immune checkpoint proteins
Cancers (Basel)20250

Clinical Studies 1

Sources: ClinicalTrials, EU CTIS

Synthesis

By phase:

N/A 1

By status:

Completed 1

By type:

Interventional 1

By Monocentric/Multicentric:

monocentric 0
multicentric2to4 0
multicentric5to9 0
multicentricup10 1

Main Topics

LeadR Networks

Main global connection map